Bipolar

OM1 a leading real-world data, outcomes and technology company with a focus on chronic conditions, today announced the enhancement of its Mental Healt.

In addition, over [$280 billion](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fstore.samhsa.gov%2Fsites%2Fdefault%2Ffiles%2Fd7%2Fpriv%2Fsma14-4883.pdf&esheet=53353797&newsitemid=20230302005039&lan=en-US&anchor=%24280+billion&index=5&md5=c89ddec9a80423c1a7f44693b063cf73) is spent annually on mental health services and nearly [one in five US adults](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fstatistics%2Fmental-illness&esheet=53353797&newsitemid=20230302005039&lan=en-US&anchor=one+in+five+US+adults&index=6&md5=7c40c2739b252ff8d39f5f046593fe19) live with a mental illness. By applying best-in-class extraction techniques, including unique AI and machine learning modeling capabilities, OM1 has the ability to harness real-world data from clinical notes obtained from its mental health network of more than 9,000 clinicians working in 2,500 clinics across all 50 states. Carl Marci, Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1. Leveraging its extensive clinical networks, unparalleled technology, and industry-leading artificial intelligence platform, OM1 offers enriched healthcare datasets, advanced platforms for regulatory-compliant real-world studies, and personalized medicine solutions. The data is part of the larger OM1 Mental Health Network of more than 3 million patients, making it the largest specialty network of its kind in the U.S. OM1 is re-imagining real-world data and evidence by developing large, electronically-connected networks of health data in immunology, cardiometabolic, mental health, neuroscience, respiratory, and ENT specialty areas. By introducing enhanced data from more than 148,000 patients with schizophrenia and bipolar, OM1 paves the way for unmatched clinical depth and novel research insights. "With increased clinical development and new medications coming to market, it’s imperative to understand how these treatments are working across patients in the real world," said Dr. "Using our vast Mental Health and Neuroscience Network with deep clinical data allows for optimal and personalized treatment plans for patients, ultimately driving improved care and outcomes.” Understanding the complexity of mental health diseases, including the varying factors affecting access to treatment, is key to personalizing patient care, improving outcomes and broadening payer coverage. It is available now for industry partners to further understand disease progression, patient characteristics, condition subtypes as well as the costs and clinical outcomes of treatments in the real world. “Using our vast Mental Health and Neuroscience Network with deep clinical data allows for optimal and personalized treatment plans for patients, ultimately driving improved care and outcomes.”